Kim Boericke, CEO, Veristat, touches on how early strategic consulting, data analytics, and automation help optimize trial design, define realistic patient populations, and generate faster insights.

Sanofi appointed Belén Garijo as its new chief executive officer, marking a leadership transition as the company enters its next strategic phase. Garijo formally assumes the role at the close of ...

The pharmaceutical industry invests billions of dollars 1 in digital tools and technologies. But for all the online surveys, feedback loops, and digital portals introduced to improve the patient ...

FDA clearance covers pembrolizumab plus paclitaxel ± bevacizumab for PD-L1 CPS ≥1 platinum-resistant disease after one or two prior systemic regimens, introducing PD-1 inhibition into this treatment ...

A regulatory setback for Moderna’s next-generation flu vaccine underscores mounting scrutiny of late-stage trial design in the U.S., even as the company pivots to international manufacturing ...

Today, that includes practices that exert price pressures designed to favor domestic companies, such as value-based ...

Yerem Yeghiazarians founder, CEO of Soley Therapeutics, talks about how drug discovery is a team effort, noting that success ...

In a separate financing round, Pandorum Technologies announced the close of an $18 million Series B financing to support the ...

Ken Banta and Andrew Hall share insights on leading through uncertainty—covering culture, capital, risk, and the regulatory ...

In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisory services, QuantX Biosciences and Pandorum ...

Eli Lilly reinforced its push into next-generation immunology and oncology innovation through two major transactions: the ...

Yerem Yeghiazarians founder, CEO of Soley Therapeutics, discusses how Soley uses human cells to guide drug discovery, ...